CANINE ATOPIC DERMATITIS TREATMENT DRUGS MARKET ANALYSIS

Market Concentration and Competitive Landscape

Close-monitor your Competitor's Move, Request sample copy

Canine atopic dermatitis (AD) is a complex disease with multiple contributing factors. It is characterized as an inflammatory and pruritic allergic skin condition that often occurs in dogs with a genetic predisposition and is associated with the production of immunoglobulin E (IgE) in response to environmental allergens. The most common and clinically significant feature of CAD is moderate to severe pruritus, which is accompanied by, and typically precedes, erythema, erythematous macular and/or popular eruptions, self-induced alopecia, excoriations, hyperpigmentation, and lichenification. According to the American College of Veterinary Dermatology (ACVD), the estimated prevalence of AD in dogs is approximately 10-15%. Furthermore, as per the data published in Blackmores, a leading natural health company, in September 2020, atopic dermatitis is the second most prevalent allergic skin disease in dogs. Golden Retriever, German Shepherd, Labrador, and Pug breeds have been proven to be the most prone to canine atopic dermatitis. Canine AD is a chronic condition that significantly affects a dog's quality of life. Itchy and inflamed skin can cause discomfort, pain, and distress for affected dogs. As pet owners prioritize their pets' well-being and seek to improve their quality of life, they are more inclined to explore and invest in effective treatments. Thus, emphasis on improving the quality of life for dogs with AD drives the market growth.